Fimasartan: A new armament to fight hypertension

Hypertension is a major public health problem of modern era. Fimasartan is a new Angiotensin Receptor Blocker approved for treatment of hypertension. It is more potent and longer acting angiotensin receptor blocker with effects lasting over 24 hours. Many clinical studies have affirmed its role in p...

Descripción completa

Detalles Bibliográficos
Autores principales: Pradhan, Akshyaya, Gupta, Vikas, Sethi, Rishi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691418/
https://www.ncbi.nlm.nih.gov/pubmed/31463228
http://dx.doi.org/10.4103/jfmpc.jfmpc_300_19
_version_ 1783443377705975808
author Pradhan, Akshyaya
Gupta, Vikas
Sethi, Rishi
author_facet Pradhan, Akshyaya
Gupta, Vikas
Sethi, Rishi
author_sort Pradhan, Akshyaya
collection PubMed
description Hypertension is a major public health problem of modern era. Fimasartan is a new Angiotensin Receptor Blocker approved for treatment of hypertension. It is more potent and longer acting angiotensin receptor blocker with effects lasting over 24 hours. Many clinical studies have affirmed its role in pharmacotherapy of hypertension. Further, it is renoprotective and has proven beneficial in diabetes also. This article briefly discusses the pharmacology and clinical evidence with fimasartan with a short summary of previous angiotensin receptor blockers.
format Online
Article
Text
id pubmed-6691418
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-66914182019-08-28 Fimasartan: A new armament to fight hypertension Pradhan, Akshyaya Gupta, Vikas Sethi, Rishi J Family Med Prim Care Review Article Hypertension is a major public health problem of modern era. Fimasartan is a new Angiotensin Receptor Blocker approved for treatment of hypertension. It is more potent and longer acting angiotensin receptor blocker with effects lasting over 24 hours. Many clinical studies have affirmed its role in pharmacotherapy of hypertension. Further, it is renoprotective and has proven beneficial in diabetes also. This article briefly discusses the pharmacology and clinical evidence with fimasartan with a short summary of previous angiotensin receptor blockers. Wolters Kluwer - Medknow 2019-07 /pmc/articles/PMC6691418/ /pubmed/31463228 http://dx.doi.org/10.4103/jfmpc.jfmpc_300_19 Text en Copyright: © 2019 Journal of Family Medicine and Primary Care http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Review Article
Pradhan, Akshyaya
Gupta, Vikas
Sethi, Rishi
Fimasartan: A new armament to fight hypertension
title Fimasartan: A new armament to fight hypertension
title_full Fimasartan: A new armament to fight hypertension
title_fullStr Fimasartan: A new armament to fight hypertension
title_full_unstemmed Fimasartan: A new armament to fight hypertension
title_short Fimasartan: A new armament to fight hypertension
title_sort fimasartan: a new armament to fight hypertension
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691418/
https://www.ncbi.nlm.nih.gov/pubmed/31463228
http://dx.doi.org/10.4103/jfmpc.jfmpc_300_19
work_keys_str_mv AT pradhanakshyaya fimasartananewarmamenttofighthypertension
AT guptavikas fimasartananewarmamenttofighthypertension
AT sethirishi fimasartananewarmamenttofighthypertension

Ejemplares similares